TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE D-

NCT07504458: Pivotal Open-label Phase 3 Clinical Study of QTX-2101 in Adult Patients With Acute Promyelocytic Leukemia

Sponsor: Quetzal Therapeutics · Phase: PHASE3 · Area: ONCOLOGY · Target Enrollment: 150 pts

Competing Trials Overlap

14 Active Trials

Excess Burn Exposure

$5,051,508

Rescue Site Savings

+$3,345,804

Unlock Full NCT07504458 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07504458 Rescue Dossier →